By providing your email address below, you are providing consent to INOVIO to send you the requested Investor Email Alert updates. Want to see which stocks are moving? “For more than a decade, INOVIO has been working closely with regulators to assess DNA medicines for their potential in disease prevention and treatment, especially for emerging infectious diseases. Market data powered by FactSet and Web Financial Group.
The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Investing in healthcare and cannabis is his passion, as well as looking out for new, actionable stock investment ideas in these sectors. Benzinga does not provide investment advice. Register to receive email alerts for INOVIO press releases Email Alerts. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Sign Up. In just one year, Inovio's total shares outstanding has ballooned from about 100 million to 167.5 million. The first time that I wrote about Inovio Pharmaceuticals (NASDAQ:INO) in Jan. 2020, it traded at just $4.86 per share .INO stock subsequently soared to $27 in July. Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. Which company executives are buying and selling shares of Inovio Pharmaceuticals (NASDAQ:INO) stock? At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Subscribe for updates from inovio . Since reaching an all-time high of $33 per share on June 29, Inovio Pharmaceuticals (NASDAQ:INO) is down nearly 61%, turning an investment of $10,000 at … Subscribe for updates from inovio . Yes! Inovio Pharmaceuticals stock news. Returns as of 11/06/2020. "We look forward to hearing back from the FDA in November and continue to prepare for a planned phase-II/III trial of INO-4800," Inovio said in a statement. All rights reserved. Zhiyuan Sun is a statistician with a knack for analyzing clinical trials and company financials. You can sign up for additional alert options at any time. Fool since April 2020.
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Since reaching an all-time high of $33 per share on June 29, Inovio Pharmaceuticals (NASDAQ:INO) is down nearly 61%, turning an investment of $10,000 at its peak to just $3,933 …
ET). QQQ 274.65 (+1.73%) AAPL 110.44 (+1.54%) MSFT 206.43 (+2.03%) FB 265.30 (+1.51%) GOOGL 1,645.66 (+1.31%) AMZN 3,048.41 (+1.46%) TSLA 423.90 (+5.84%) NVDA 520.78 (+3.49%) BABA 285.57 (-8.13%) CGC 20.46 ( … After submitting your request, you will receive an activation email to the requested email address.
The FDA is mandated to reply to the response submitted by the company within 30 days. Log In. In just one year, Inovio's total shares outstanding has ballooned from about 100 million to 167.5 million. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) trade information. While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. If you experience any issues with this process, please contact us for further assistance. Share your opinion and gain insight from other stock traders and investors. SEC Filings. Investors who anticipate trading during these times are strongly advised to use limit orders. By the end of 2023, the top eight coronavirus vaccine players would likely be able to address the vast majority of global demand for immunization.
Identify stocks that meet your criteria using seven unique stock screeners. Historical Stock Quote. © 2020, Nasdaq, Inc. All Rights Reserved. Moreover, INO-4800 did not appear as a candidate on the list of coronavirus vaccine developers for the U.S. government's Operation Warp Speed back in June. To see all exchange delays and terms of use please see disclaimer. Stock prices may also move more quickly in this environment. Corporate Governance. View which stocks are hot on social media with MarketBeat's trending stocks report. What's Next For Inovio: Inovio is scheduled to report its third-quarter results Monday after the close.The company may shed some light on the potential resolution of the partial clinical hold and the vaccine timeline in the earnings report or in the call.INO Price Action: In premarket trading Monday, Inovio's shares were up 0.7% at $10.09.Related Link: Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure * A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios(C) 2020 Benzinga.com. Today, let's look at what's going on behind Inovio and why investors should look for, Inovio's progress is in stark contrast to that of its competitors, such as, When a company continuously loses cash, it must raise more money from investors to stay afloat. Keep in mind, the world only needs between 7.8 billion and 15.6 billion doses of COVID-19 vaccines for complete global immunization (some vaccine candidates require one dose, some two). Back in August, Inovio published interim phase 1/2 clinical results (pending peer review) regarding INO-4800, its DNA-based COVID-19 vaccine candidate. Register to receive email alerts for INOVIO press releases Email Alerts. These companies aren't about to win the coronavirus vaccine race, but their competitors probably will. You must click the activation link in order to complete your subscription. See you at the top! MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. © 2020 Verizon Media. Sporting 1.73% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Oct 27 when the INO stock price touched $11.20- or saw a rise of 10.54%. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Trending now. Inovio's progress is in stark contrast to that of its competitors, such as Pfizer (NYSE:PFE) (which is collaborating with BioNTech (NASDAQ:BNTX)), Moderna (NASDAQ:MRNA), AstraZeneca (NASDAQ:AZN), Novavax (NASDAQ:NVAX), Johnson & Johnson (NYSE:JNJ), and CureVac (NASDAQ:CVAC), all of which are either negotiating or have already secured more than 1 billion doses' worth of orders for their COVID-19 vaccine candidates from the governments of developed countries worldwide.
Start Your Risk-Free Trial Subscription Here, 3 Stocks to Buy that Could Benefit from Recent Voting Results, Lancaster Colony Corporation (NASDAQ:LANC) Is About To Raise The Dividend, More Gains for Barrick Gold (NYSE:GOLD) Make it Worth a Look, It’s Time For Another Slice Of Papa John’s International (NASDAQ:PZZA), Here’s Where to Ring the Register on Snap (NASDAQ: SNAP) Stock, Cardinal Health (NYSE:CAH) Is A Great Buy For Patient Investors, Swipe Right on Match Group (NASDAQ: MTCH), There's Always Next Year: 3 Stocks Set to Bounce Back in 2021, Expeditors International (NASDAQ:EXPD) Double-Digit Growth Not Enough For Investors, Second Chance Sale: 3 Stocks That Look Attractive After the Market Selloff, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, 8 Stocks That Robinhood Investors Got Right, 7 Stocks That Will Help You Forget About the Fed, Receive Analysts' Upgrades and Downgrades Daily.
Find the latest Inovio Pharmaceuticals, Inc. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. Investors looking for coronavirus vaccine stocks may wish to consider Inovio's, Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Is Everyone Talking About Inovio Stock? )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field11.add(Validate.Presence, {failureMessage:"This field is required"});field11.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i
Once vaccinated, a patient would not need a subsequent dose for an extended period, effectively cutting out the possibility for manufacturers to generate recurring cash flows. © American Consumer News, LLC dba MarketBeat® 2010-2020. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target... CEPI to fund development of COVID-19 vaccine candidate by China's Clover, Stock lenders wince as hedge funds lose their shorts, Danger Is Approaching for Coronavirus Vaccine Stocks -- Heard on the Street.